

Introduction

- The Keynote 775 trial compared pembrolizumab and lenvatinib to chemotherapy alone in patients with endometrial cancer who had previously received platinum-based chemotherapy¹
- This study noted improved overall survival with lenvatinib and pembrolizumab in both the mismatch repair-proficient (pMMR) subgroup and in the overall population¹
- This regimen is currently recommended by the National Comprehensive Cancer Network (NCCN) as a category 1 recommendation for patients with recurrent pMMR disease²
- Currently, there is a lack of treatment options for second line or subsequent therapy for recurrent endometrial cancer. The regimen of pembrolizumab and lenvatinib is the only category 1 recommendation made by the NCCN in this setting²
- Although the study started patients on lenvatinib 20 mg daily, the median tolerated dose was 13.8 mg¹
- This study aims to characterize the use of lenvatinib and toxicities requiring modifications in therapy in clinical practice

Objectives

- **Primary outcome:** Percentage of patients that require dose adjustments at each initiation dose
- **Secondary outcomes:** Assessment of the starting and ending doses and the toxicities associated with each therapy modification (defined as a dose reduction, hold in therapy, or discontinuation of therapy)

Methods

- Single-center, retrospective chart review
- **Data Collection Points:** Number of therapy modifications (defined as a dose reduction, hold in therapy, or discontinuation of therapy), reason associated with therapy modifications, initiation dose, subsequent dosing, and baseline characterizes (listed in Table 1)

Inclusion Criteria

- Diagnosis of endometrial cancer
- Prescribed lenvatinib by a University Hospitals gynecologic oncologist between July 2021 and August 2023

Assessment of Lenvatinib Toxicity Profile in Patients with Endometrial Cancer

Tiffany Chan, PharmD¹; Sharon Zhong, PharmD¹; Jeffrey Pasucal, PharmD, AAHIVP¹; Vineet Gopinathan, PharmD¹ ¹University Hospitals Cleveland Medical Center

Results

Table 1. Baseline Cha

Age at initiation - years (IQR)

Number of previous therapies (Rar

Patient with CrCl > 30 ml/min at initiation

Patients with Child-Pugh C status a initiation

On antihypertensives at baseline

On thyroid supplementation at base *Expressed as n (%) unless otherwise specified

Figure 1. Patients requiring dose reductions based on initiation doses

- Patient started on that dose





Table 2. Ending Doses Prior to Discontinuation at Each Initiation

Dose			
	Median Ending	Percent Dose	Median number of
Dose (mg)	Dose (mg)	Reduction	therapy modifications
8 (n = 2)	6	25%	3.5
10 (n = 7)	10	0%	0
14 (n = 16)	10	28%	1
20 (n = 2)	9	55%	3

aracteristics (n = 27)*			
	68 (63.5 – 73.5)		
nge)	1 (1-2)		
	27 (100)		
at	0 (0%)		
	17 (62)		
seline	3 (11)		
	• • • •		



3;386(5):437-448.





Results (Continued)

- 2. Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Feb;21(2):181-209.